Effects of Bifidobacterium animalis subsp. lactis HN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis.
- 2020-02-19
- Beneficial Microbes 11(1)
- R. S. Cardoso
- M. Messora
- P. Silva
- L. F. Oliveira
- C. Leite-Panissi
- S. Salvador
- R. Casarin
- A. B. Novaes
- D. Palioto
- F. Furlaneto
- PubMed: 32066256
- DOI: 10.3920/bm2019.0038
Abstract
The purpose of this study was to evaluate the effects of systemic administration of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) on ligature-induced periodontitis in rats with experimental rheumatoid arthritis (RA). 28 rats were divided into four groups (n=7): RA (rheumatoid arthritis), RA/PROB (probiotic), RA/EP (experimental periodontitis) and RA/EP/PROB. From day zero, HN019 was added daily to the water of the PROB groups animals until the end of the experiment. From day seven, RA was induced. On day 28, in EP groups, ligatures were positioned around mandibular first molars and remained in position for 11 days, in order to induce periodontitis. The animals were euthanised on day 39. Microtomographic, histomorphometric, immunoenzymatic and microbiological analyses were performed. Data were statistically analysed (P<0.05). Group RA/EP/PROB presented reduced alveolar bone loss, tumour necrosis factor-α and interleukin (IL)-6 levels and increased IL-17 levels when compared with group RA/EP. There were no significant differences regarding connective tissue attachment level and IL-10 levels between groups RA/EP and RA/EP/PROB. Group RA/PROB showed decreased anti-citrullinated protein antibodies levels when compared with groups RA and RA/EP. Group RA/EP/PROB presented a higher rate of aerobic/anaerobic bacteria than group RA/EP. Systemic administration of HN019 promoted a protective effect against periodontal tissue destruction, decreasing both bone loss and inflammatory mediators and increasing the proportion of bacteria compatible with periodontal health, in rats with experimental RA and EP.
Keywords: bone resorption; periodontal disease; probiotics; rheumatic diseases.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium animalis subsp. lactis HN019 | Increased Aerobic to Anaerobic Bacteria Ratio | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Increased IL-17 Levels | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Large |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Anti-citrullinated Protein Antibodies Levels | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Reduced Proinflammatory Mediators | Beneficial | Large |
Bifidobacterium lactis HN019 | Elevated Interleukin-17 Levels | Beneficial | Small |
Bifidobacterium lactis HN019 | Increased Proportion of Aerobic and Anaerobic Bacteria | Beneficial | Moderate |
Bifidobacterium lactis HN019 | No Change in Interleukin-10 Levels | Neutral | Small |
Bifidobacterium lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Large |
Bifidobacterium lactis HN019 | Reduced Anti-citrullinated Protein Antibodies Levels | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Reduced Interleukin-6 Levels | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Stabilized Connective Tissue Attachment Levels | Neutral | Small |